<DOC>
	<DOCNO>NCT02409030</DOCNO>
	<brief_summary>The purpose study validate diagnostic test combine different blood marker identify correctly classify patient Alzheimer 's disease ( AD ) compare individual behavioural variant frontotemporal dementia ( bvFTD , patient control ) versus cognitively healthy individual ( healthy control ) .</brief_summary>
	<brief_title>Multi-parameter Diagnostic Blood Test Diagnosis Alzheimer 's Disease</brief_title>
	<detailed_description>The purpose study validate new multi-parameter diagnostic test , well-characterised population base new AD diagnostic criterion , combine different type marker , select base prior exploratory study carry Raman Health Technologies .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1 . Healthy control : Aged 5080 year . Men woman . Assessment neuropsychological test confirm absence cognitive impairment . Prior participant inclusion , obtain result CerebroSpinal Fluid marker analysis ( betaamyloid , Tau protein pTau ) carry 24 month recruitment . 2 . Patients diagnose Alzheimer 's disease ( AD ) . Aged 5080 year . Men woman . Patients meet clinical criterion Alzheimer 's disease : Prior participant inclusion , result obtain CerebroSpinal Fluid marker analysis ( betaamyloid , Tau protein pTau ) carry 36 month recruitment . 3 . Patients behavioural variant frontotemporal dementia primary progressive aphasia : Aged 5080 year . Men woman . Patient meet clinical criterion behavioural variant frontotemporal dementia ( bvFTD ) , syndromes associated temporal variant affect language ( primary progressive aphasia , agrammatic semantic subgroup ) : ( Mild Cognitive Impairment ) substudy : Patients mild cognitive impairment include Aged 5080 year . Men woman . Patient meet clinical criterion mild cognitive impairment : Clinical diagnostic criterion mild cognitive impairment : NIAAlzheimer 's Association America criterion , Alzheimer 's Dementia , 2011 Prior participant inclusion , result obtain cerebrospinal fluid marker analysis ( betaamyloid , Tau protein pTau ) carry 12 month recruitment . Severe acute systemic disease could impede participant 's followup study : Advanced liver kidney disease disseminate neoplastic disease Addiction alcohol drug last two year base Diagnostic Statistical Manual Mental Disorders IV criterion , except nicotine use , permit Down 's syndrome Moderate severe head injury central nervous system infection ( HIV , syphilis , borrelia , herpes simplex , suspected CreutzfeldtJakob disease ) Endocrine alteration ( thyroid alteration ) Nutritional deficiency ( vitamin B12 , folic acid ) Clinical history stroke previous three month neuroimaging evidence clinically significant cardiovascular disease ( e.g . strategic infarct severe leukoencephalopathy ) . Neurological disease ( dysmyelinating disorder , Parkinson 's disease , Huntington 's disease , normal pressure hydrocephalus , subdural haematoma , brain tumour ) Major psychiatric disorder ( major depression psychosis ) Patients clearly defined clinical diagnosis accord study group ( inclusion/exclusion criterion ) Disease , investigator 's sponsor 's judgement , may potentially significant influence thus generate bias study marker .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>